DOSSIER BATCH INFORMATION

Notes:

1. Clinical data are included as proof of efficacy. In the relative bioavailability study 1218.25, which compares early clinical trial formulations, three batches were used: B061002729, B06100185 and B061002680. The batch information on these three batches are included under the heading "Relative bioavailability".
2. The composition of the iFF (intended final formulation) used in the phase III clinical trials and the FF (final formulation) are almost identical except that in the FF only the colourant iron oxide yellow was omitted.

	3.2.P.3	**3.2.P.5**	**3.2.P.8**	**3.2.P & Module 5**	
	Manufacture	**Control of final pharmaceutical product**	**Stability**	**Relative bioavailability**	**Dissolution** **(Refer notes below for dissolution methods)**
1. Type of batches	Experimental	Experimental			Experimental
2. Lot number	B050411	B050411			B050411 (Apparatus 1 and 2)
3. Lot size	2 kg	2 kg			2 kg
4. Date of manufacture	May 2005	May 2005			May 2005
5. Site/s of FPP manufacture	1*	1*			1*
6. Formulation and manufacturing process as applied for (Y/N) (clarify if not)	No TF-II**	No TF-II**			No TF-II**
7. Site of API	Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany	Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany			Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany

	3.2.P.3	3.2.P.5	3.2.P.8	3.2.P & Module 5	
	Manufacture	**Control of final pharmaceutical product**	**Stability**	**Relative bioavailability**	**Dissolution** **(Refer notes below for dissolution methods)**
1. Type of batches	Experimental	Experimental			Experimental
2. Lot number	B051001015	B051001015			B051001015 (Apparatus 2)
3. Lot size	18 kg	18 kg			18 kg
4. Date of manufacture	Oct. 2005	Oct. 2005			Oct. 2005
5. Site/s of FPP manufacture	1*	1*			1*
6. Formulation and manufacturing process as applied for (Y/N) (clarify if not)	No TF-IIb**	No TF-IIb**			No TF-IIb**
7. Site of API	Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany	Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany			Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
1. Type of batches	Experimental	Experimental		Experimental	Experimental
2. Lot number	B061001855	B061001855		B061001855	B061001855 (Apparatus 1 and 2)
3. Lot size	13 kg	13 kg		13 kg	13 kg
4. Date of manufacture	Aug. 2006	Aug. 2006		Aug. 2006	Aug. 2006

***Manufacturing sites**:
1 – Boehringer Ingelheim Pharma GmbH & Co. KG, XXXXXXX Germany (development site)
2 - Boehringer Ingelheim ZZZZZZZZZZZZZZ (commercial site)

****Formulation variants:**
TF-II –trial formulation II
TF-IIb – trial formulation IIb
iFF – intended final formulation (the film-coating contains iron oxide yellow and iron oxide red as colorants)
FF – final formulation (the film-coating contains iron oxide red as the only colorant; identical to the composition of the commercial drug product as described in section 3.2.P.1.

Notes on Site of API: (refer Module 3, section 3.2.S.2.6 – Manufacturing Process Development, p6 of 11)
During development the chemical process was improved stepwise and adjusted to the requirements of scale up and the commercial site resulting in 5 different variants.
Throughout the development of the current process (synthesis route II) there have been only minor changes to the manufacturing process.
These variants differ only in changes of solvents, process parameters and procedures for work up (variant II/A, II/B, II/C, II/D and II/E).
Variants II/A – II/C and step 1 and step 3-C of variant II/D were developed and performed at **site XXXXXXX(Germany) until 2005.**
Step 2, step 3-A and step 3-B of variants II/D as well as variant II/E were developed and performed at the commercial **site YYYYYYY (Germany).**

Notes on dissolution method:
Refer to Module 3, section 3.2.P.5.4 – Batch Analyses, p. 20 of 22.